SET domain containing 5Genealiases: MRD23 · SETD5A
Q-omics provides the consensus-scored SETD5 profile across patient tissues and cancer cell-line models. SETD5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SETD5 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, SETD5 RNA expression shows 21,723 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where SETD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SETD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SETD5 survival associations across molecular data types. SETD5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (12) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SETD5 RNA expression–survival associations across cancer types. High SETD5 expression shows unfavorable associations in ACC, MESO, LIHC, KICH and LUSC, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SETD5 RNA expression.
This table summarizes SETD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SETD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SETD5 shows higher tumor expression in COAD, BLCA, LIHC, CHOL, HNSC and READ. The COAD box plot shows higher SETD5 RNA expression in tumor versus normal tissue (log2 FC = +0.626, t-test p < 0.001).
This table shows molecular features associated with SETD5 in patient tissues and cancer cell lines. In patient samples, SETD5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SETD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
